René Classens

René Classens

Auto-generated profile, based on publicly available information

René Classens

Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, the Netherlands

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2023 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
RMRui Santalla Méndez
Rui Santalla Méndez
AFAndrea Rodgers Furones
Andrea Rodgers Furones
RCRené Classens
René Classens
KFKristina Fedorova
Kristina Fedorova
MHManon Haverdil
Manon Haverdil
LCLaia Querol Cano
Laia Querol Cano
Intracellular vesicle transport is essential for cellular homeostasis and is partially mediated by SNARE proteins. Endosomal trafficking to the plasma membrane ensures cytokine secretion in dendritic cells (DCs) and the initiation of immune responses. Despite its critical importance, the specific molecular components that regulate DC cytokine secretion are poorly characterised. Galectin-9, a ß-galactoside-binding protein, has emerged as a novel cellular modulator although its exact intracellular roles in regulating (immune) cell homeostasis and vesicle transport are virtually unknown. We investigated galectin-9 function in primary human DCs and report that galectin-9 is essential for intracellular cytokine trafficking to the cell surface. Galectin-9-depleted DCs accumulate cytokine-containing vesicles in the Golgi complex that eventually undergo lysosomal degradation. We observed galectin-9 to molecularly interact with Vamp-3 using immunoprecipitation-mass-spectrometry and identified galectin-9 was required for rerouting Vamp-3-containing endosomes upon DC activation as the underlying mechanism. Overall, this study identifies galectin-9 as a necessary mechanistic component for intracellular trafficking. This may impact our general understanding of vesicle transport and sheds new light into the multiple roles galectins play in governing cell function. Graphical abstract

23 September 2025 in Journal of Cell Biology
Verified
Journal Article
Open access
GFGuus A. Franken
Guus A. Franken
HWHarry Warner
Harry Warner
JCJorge Cuenca-Escalona
Jorge Cuenca-Escalona
ISIsabel F. Stehle
Isabel F. Stehle
VRVince P.A. van Reijmersdal
Vince P.A. van Reijmersdal
LCLaia Querol Cano
Laia Querol Cano
Adaptive immunity relies on dendritic cell (DC) migration to transport antigens from tissues to lymph nodes. Galectins, a family of β-galactoside–binding proteins, control cell membrane organization, exerting crucial roles in multiple physiological processes. Here, we report a novel mechanism underlying cell polarity and uropod retraction by demonstrating that galectin-9 regulates basal and chemokine-driven DC migration in humans and mice. Galectin-9 depletion caused a defect in RhoA signaling that resulted in impaired cell rear contractility. Mechanistically, galectin-9 interacts with and organizes CD44 at the cell surface, in turn modulating RhoA binding to GEF-H1 and the initiation of downstream signaling. Analysis of DC motility in the 3D tumor microenvironment revealed galectin-9 is also required for DC recruitment and infiltration. Exogenous galectin-9 rescued the motility of tumor-immunocompromised human blood DCs, validating the physiological relevance of galectin-9 in DC migration. Our results identify galectin-9 as a necessary mechanistic component for DC motility by regulating cell polarity and contractility, and underscore its implications for DC-based immunotherapies.

5 May 2025 in RSC Chemical Biology
Verified
Journal Article
Open access
PDF file
ZWZacharias Wijfjes
Zacharias Wijfjes
ITIván Ramos Tomillero
Iván Ramos Tomillero
CGCamille M. Le Gall
Camille M. Le Gall
EDEric A. W. van Dinther
Eric A. W. van Dinther
FTFrederique Turlings
Frederique Turlings
MVMartijn Verdoes
Martijn Verdoes
The aim of therapeutic cancer vaccines is to induce tumor-specific cellular immune responses. This requires tumor antigens to be efficiently processed and presented by antigen-presenting cells, in particular dendritic cells (DCs). In addition, DCs require maturation to upregulate the surface expression and secretion of T cell costimulatory molecules, which is achieved by co-administration of adjuvants in vaccines. Peptide-based antigen vaccination is an attractive strategy due to the established biocompatibility of peptides as well as the dosing control. To enhance the efficacy of peptide-based vaccines, antigens can be targeted to DCs. Antigen–adjuvant conjugates are known to enhance T cell activation by ensuring DC maturation upon antigen delivery. In this study, we aim to combine these two approaches in a single molecule, and present a DC-targeted antibody fragment–antigen–adjuvant (AAA)-conjugate. We generate the AAA-conjugate through a combination of site-specific sortase-mediated chemoenzymatic ligation and click chemistry. Ex vivo T cell activation assays show enhanced efficacy of the AAA-conjugate compared to non-adjuvanted control conjugates. The in vivo performance of the AAA-conjugate was suboptimal, which we hypothesize to be a consequence of the hydrophobic character of the conjugate. In vivo efficacy was rescued by co-administration of antibody fragment–antigen conjugates and antibody fragment-adjuvant conjugates, in which the antigen and adjuvant were separatedly delivered using two different DC-targeting molecules. In conclusion, this study provides a proof-of-concept for effective in vivo antigen-specific T cell activation by targeted delivery of both antigen and adjuvant to DCs in a single or separate molecule using site-specific protein engineering.

9 November 2024 in Acta Biomaterialia
Verified
Journal Article
Open access
LWLea Weiss
Lea Weiss
MSMarjolein Schluck
Marjolein Schluck
RCRené Classens
René Classens
PJPaul K.J.D. de Jonge
Paul K.J.D. de Jonge
AWAnniek van der Waart
Anniek van der Waart
RHRoel Hammink
Roel Hammink
Immunotherapies are a powerful strategy to treat cancer by modulating the immune system to raise an anti-tumor immune response. A prime example of immunotherapies are cytokines - small immunomodulatory molecules that are widely used to stimulate immune cells. Undirected administration of cytokines, however, can cause severe side effects, preventing the use of potent cytokines, such as Interleukin (IL)-12, which induces IFNγ responses by cytotoxic effector lymphocytes, including NK cells. Biomaterials, like nanoparticles, can encapsulate IL-12 and accumulate at the tumor site to alleviate side effects. Yet, the released IL-12 might not be directly targeted to extracellular IL-12 receptors on the specific effector cells, thereby potentially compromising the cytokine's therapeutic efficacy. Here, we develop a polymer-based platform to target NK cells, which we call immunofilaments. Immunofilaments are nanosized linear polymers that present an anti-CD16 antibody and IL-12 effectively to NK cells and lead to synergistic NK cell activation as highlighted by an increase in TNFα and IFNγ production and upregulation of multiple activation markers, including CD25, CD69, and degranulation marker CD107a. NK cell proliferation is enhanced in the presence of both anti-CD16 antibody and IL-12 compared to giving IL-12 separately. Finally, we demonstrate that the IF platform is suitable for in vivo applications, as immunofilaments readily activate human NK cells upon administration to mice. STATEMENT OF SIGNIFICANCE: IL-12 is a potent cytokine that stimulates IFNγ responses in NK cells, which supports an anti-tumor immune response. Due to its high potency, the delivery of IL-12 needs to be highly controlled to prevent severe adverse side effects, which can be achieved by using biomaterials. This study shows that nanosized polymers termed Immunofilaments can be used to immobilize IL-12 and effectively target and activate NK cells by co-conjugation of anti-CD16 antibodies. This work is a prime example of careful engineering of innovative biomaterials to improve immunotherapy.

1 November 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
GFGuus Franken
Guus Franken
JCJorge Cuenca-Escalona
Jorge Cuenca-Escalona
ISIsabel Felicitas Stehle
Isabel Felicitas Stehle
VRVince van Reijmersdal
Vince van Reijmersdal
AFAndrea Rodgers Furones
Andrea Rodgers Furones
SDSefania Diblasio
Sefania Diblasio
Adaptive immunity relies on dendritic cell (DC) migration to transport antigens from tissues to lymph nodes. Galectins, a family of β-galactoside-binding proteins, control cell membrane organisation, exerting crucial roles in multiple physiological processes. Here, we report a novel mechanism underlying cell polarity and uropod retraction. We demonstrate that galectin-9 regulates chemokine-driven and basal DC migration both in humans and mice, indicating a conserved function for this lectin. We identified the underlying mechanism, namely a deficiency in cell rear contractility mediated by galectin-9 interaction with CD44 that in turn regulates RhoA activity. Analysis of DC motility in the 3D tumour-microenvironment revealed galectin-9 is also required for DC infiltration. Moreover, exogenous galectin-9 rescued the motility of tumour-immunocompromised human blood DCs, validating the physiological relevance of galectin-9 in DC migration and underscoring its implications for DC-based immunotherapies. Our results identify galectin-9 as a necessary mechanistic component for DC motility and highlight a novel role for the lectin in regulating cell polarity and contractility.

4 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
AFAndrea Rodgers Furones
Andrea Rodgers Furones
TBThijs Brands
Thijs Brands
KFKristina Fedorova
Kristina Fedorova
ZWZacharias Wijfjes
Zacharias Wijfjes
RCRené Classens
René Classens
LCLaia Querol Cano
Laia Querol Cano
To initiate T cell-mediated immunity, dendritic cells (DCs) present antigens to specific T cells through the establishment of an immune synapse (IS). While the molecular mechanisms behind the formation of the IS on the T cell side are well understood, how IS components are organized at the DC membrane remain ill-defined. Galectins, a family of β-galactoside binding proteins, modulate immune cell function via the establishment of specific glycan-dependent or independent interactions. Nonetheless, the molecular mechanisms that underlie galectin function are poorly described and very little is known regarding their contribution to DC-mediated T cell activation. Here, we demonstrate that intracellular galectin-9 (gal9) in DCs is required for T cell activation. Murine and human DCs lacking gal9 showed impaired induction of CD4 + , but not CD8 + , T cell proliferation, suggesting a conserved function for gal9 in modulating DC–T cell interactions. Live-cell imaging revealed that galectin-9-depleted DCs fail to establish stable ISs with T cells, resulting in reduced T cell activation and proliferation. Unbiased co-immunoprecipitation and mass spectrometry identified HLA-II as a gal9 binding partner in DCs, and we observed a marked reduction of HLA-II recruitment to the immune synapse in DCs lacking gal9. Conditional gal9 knockout in DCs led to enhanced tumor growth in vivo , compared to their wild-type (WT) counterparts, underscoring a role for gal9 in T cell-dependent anti-tumor immunity. Collectively, this study provides the first detailed account of gal9-mediated HLA-II organization at the synaptic site of DCs, revealing a novel mechanism by which galectins orchestrate immune receptor positioning from within the cytoplasm to enhance CD4 + T cell activation.